Remitting–relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab

Case report

(1610) Views  (344) Full article downloads

Authors: Athanasia Mouzaki, Maria Koutsokera, Zoe Dervilli, et al

Published Date September 2010 Volume 2010:3 Pages 313 - 320

DOI: http://dx.doi.org/10.2147/IJGM.S13648

Athanasia Mouzaki¹, Maria Koutsokera², Zoe Dervilli¹, Maria Rodi¹, Dimitra Kalavrizioti^1,3, Nikolaos Dimisianos², Ioannis Matsoukas³, Panagiotis Papathanasopoulos^2
1Division of Hematology, Department of Internal Medicine, ²Neurology Clinic, Medical School and University Hospital, ³Department of Chemistry, University of Patras, Patras, Greece

Abstract: Bone marrow transplantation (BMT) was introduced as a treatment option 15 years ago for severe, drug-resistant multiple sclerosis (MS). Up until now, BMT has been undertaken in relatively few patients worldwide, with moderate success, and recent studies suggest that patients with early, highly aggressive MS benefit most from this treatment. In this work, we determined peripheral blood lymphocyte populations in a patient (patient A) with remitting–relapsing multiple sclerosis (RR-MS), refractory to conventional treatments, and who underwent BMT, relapsed, and has been treated with natalizumab for the last 22 months. Eleven other RR-MS patients in the acute phase of the disease, untreated or treated with interferon-beta, and 20 healthy subjects served as controls. Natalizumab treatment in patient A resulted in lymphocytosis and increased levels of CD20+/CD20+CD5+ B cells and T regulatory cells (Tregs). The patient maintained relatively low levels of T cells, T helper cells, memory T helper cells, and naive cytotoxic T cells, and very low levels of naive T helper cells and natural killer cells throughout. The Tregs of patient A post-treatment with natalizumab responded well in culture to a peptide mapping to a myelin basic protein antigenic epitope (mean 42% increase) compared with Tregs of healthy controls (mean 15% increase) whereas Tregs of the RR-MS controls or patient A prenatalizumab treatment either did not respond or responded adversely to the peptide (mean 3% and 21% decreases, respectively). Since the beginning of natalizumab treatment, patient A has had no relapses, and his Expanded Disability Status Score has improved. From the parameters studied, Treg responsiveness to autoantigens seems to be an important differentiating factor in RR-MS progression.

Keywords: bone marrow transplantation, lymphocytes, multiple sclerosis, myelin basic protein antigen, peptide, phenotype, remitting–relapsing, T regulatory cells

Readers of this article also read: